JP2009539348A5 - - Google Patents

Download PDF

Info

Publication number
JP2009539348A5
JP2009539348A5 JP2009513297A JP2009513297A JP2009539348A5 JP 2009539348 A5 JP2009539348 A5 JP 2009539348A5 JP 2009513297 A JP2009513297 A JP 2009513297A JP 2009513297 A JP2009513297 A JP 2009513297A JP 2009539348 A5 JP2009539348 A5 JP 2009539348A5
Authority
JP
Japan
Prior art keywords
seq
sequence
cdr
antibody
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009513297A
Other languages
English (en)
Japanese (ja)
Other versions
JP4560582B2 (ja
JP2009539348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/012950 external-priority patent/WO2007143098A2/en
Publication of JP2009539348A publication Critical patent/JP2009539348A/ja
Publication of JP2009539348A5 publication Critical patent/JP2009539348A5/ja
Application granted granted Critical
Publication of JP4560582B2 publication Critical patent/JP4560582B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009513297A 2006-06-02 2007-06-01 肝細胞成長因子（ｈｇｆ）結合蛋白質 Expired - Fee Related JP4560582B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US86046106P 2006-11-21 2006-11-21
PCT/US2007/012950 WO2007143098A2 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010167648A Division JP5528246B2 (ja) 2006-06-02 2010-07-26 肝細胞成長因子（ｈｇｆ）結合蛋白質

Publications (3)

Publication Number Publication Date
JP2009539348A JP2009539348A (ja) 2009-11-19
JP2009539348A5 true JP2009539348A5 (enExample) 2010-08-05
JP4560582B2 JP4560582B2 (ja) 2010-10-13

Family

ID=38802082

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009513297A Expired - Fee Related JP4560582B2 (ja) 2006-06-02 2007-06-01 肝細胞成長因子（ｈｇｆ）結合蛋白質
JP2010167648A Expired - Fee Related JP5528246B2 (ja) 2006-06-02 2010-07-26 肝細胞成長因子（ｈｇｆ）結合蛋白質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010167648A Expired - Fee Related JP5528246B2 (ja) 2006-06-02 2010-07-26 肝細胞成長因子（ｈｇｆ）結合蛋白質

Country Status (15)

Country Link
US (5) US7659378B2 (enExample)
EP (2) EP2380908A1 (enExample)
JP (2) JP4560582B2 (enExample)
KR (1) KR101196184B1 (enExample)
AR (1) AR061170A1 (enExample)
AT (1) ATE533787T1 (enExample)
AU (1) AU2007254853B2 (enExample)
BR (1) BRPI0712223A2 (enExample)
CA (1) CA2654019A1 (enExample)
ES (1) ES2378097T3 (enExample)
IL (2) IL195038A0 (enExample)
MX (1) MX2008015138A (enExample)
NO (1) NO20085422L (enExample)
NZ (1) NZ573819A (enExample)
WO (1) WO2007143098A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE495195T1 (de) * 2006-06-02 2011-01-15 Aveo Pharmaceuticals Inc Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e
ES2378097T3 (es) * 2006-06-02 2012-04-04 Aveo Pharmaceuticals, Inc. Proteínas de unión al factor de crecimiento de hepatocitos (HGF)
EP3009148B1 (en) 2007-07-02 2018-08-22 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
JP5646457B2 (ja) * 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CA2725873C (en) 2008-05-29 2018-05-01 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
AR072000A1 (es) 2008-06-03 2010-07-28 Abbott Lab Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
JP2011523853A (ja) * 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
US10611835B2 (en) * 2008-07-10 2020-04-07 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancer
CN102131524B (zh) 2008-11-07 2014-05-14 星系生物科技责任有限公司 成纤维细胞生长因子受体2的单克隆抗体
SG2014010573A (en) * 2008-11-12 2014-04-28 Merck Sharp & Dohme ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
KR20120060877A (ko) * 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
TW201119676A (en) * 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
SG187938A1 (en) 2010-08-26 2013-04-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
JP2014501725A (ja) 2010-11-24 2014-01-23 グラクソ グループ リミテッド Ｈｇｆを標的とする多特異的抗原結合タンパク質
EP3401329A1 (en) 2011-07-15 2018-11-14 OncoMed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
CN104159920A (zh) 2011-12-30 2014-11-19 艾伯维公司 针对il-13和/或il-17的双重可变结构域免疫球蛋白
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP6335896B2 (ja) 2012-07-13 2018-05-30 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｒｓｐｏ３結合剤およびその使用法
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
WO2014153166A2 (en) * 2013-03-14 2014-09-25 Alder Biopharmaceuticals, Inc. Therapeutic use of antibodies to hgf
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
MA40363A (fr) * 2014-08-15 2017-06-21 Oncomed Pharm Inc Agents de liaison de rspo1 et leurs utilisations
CA2961374A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
WO2016065245A1 (en) 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
EP3209769B1 (en) * 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2016205566A1 (en) * 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
WO2017172733A1 (en) * 2016-03-28 2017-10-05 The Regents Of The University Of California Anti-ryk antibodies and methods of using the same
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
CN110785185B (zh) * 2017-06-05 2024-05-24 詹森生物科技公司 具有非对称ch2-ch3区突变的工程化多特异性抗体和其他多聚体蛋白
CN119161477A (zh) * 2017-06-15 2024-12-20 纪念斯隆凯特琳癌症中心 抗l1-cam抗体及其用途
CN118638787A (zh) 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
US11155638B2 (en) 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
EP3938405A4 (en) * 2019-03-20 2022-12-28 Javelin Oncology, Inc. ANTI-ADAM12 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS THEREOF
CN114729358A (zh) 2019-08-12 2022-07-08 因特尔纳技术有限公司 涉及miRNA-193a的新疗法
CA3167367A1 (en) 2020-02-28 2021-09-02 Sanaz YAHYANEJAD Mirna-193a for promoting immunogenic cell death
IL296393B1 (en) * 2020-03-27 2025-12-01 Avidity Biosciences Inc Compositions and methods of treating muscle dystrophy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
MXPA06000508A (es) 2003-07-18 2006-04-05 Amgen Inc Agentes de union especifica al factor del crecimiento de los hepatocitos.
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
MX2007015056A (es) * 2005-06-02 2008-03-11 Galaxy Biotech Llc Metodos para el tratamiento de tumores de cerebro con anticuerpos.
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
ES2378097T3 (es) 2006-06-02 2012-04-04 Aveo Pharmaceuticals, Inc. Proteínas de unión al factor de crecimiento de hepatocitos (HGF)
ATE495195T1 (de) 2006-06-02 2011-01-15 Aveo Pharmaceuticals Inc Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법

Similar Documents

Publication Publication Date Title
JP2009539348A5 (enExample)
JP2009225799A5 (enExample)
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
JP2010246565A5 (enExample)
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2008112004A3 (en) ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
RU2531523C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2010526028A5 (enExample)
NZ585622A (en) Hepatitis c virus antibodies
WO2005016111A3 (en) Antibodies directed to parathyroid hormone (PTH) and uses thereof
JP2017114866A5 (enExample)
JP2010511388A5 (enExample)
JP2023093753A5 (enExample)
WO2006130458A3 (en) Antibodies directed to cd20 and uses thereof
JP2010535205A5 (enExample)
WO2006113643A3 (en) High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
JP2020058359A5 (enExample)
JP2018504105A5 (enExample)
NO20074867L (no) Antistoffer mot CCR5 og anvendelser derav
WO2005069970A3 (en) Antibody specificity transfer using minimal essential binding determinants
JP2013506428A5 (enExample)
JP2017512759A5 (enExample)
WO2007070432A3 (en) Binding proteins specific for insulin-like growth factors and uses thereof
NZ601342A (en) Antibodies that bind il-4 and/or il-13 and their uses